MLANA and metastatic melanoma: Given the poor five-year survival rate and prognosis of patients with late-stage melanoma, DMKN in conjunction with Melan-A and Ki67 could serve as a novel marker to distinguish lymph node naive melanoma from metastatic melanoma [79].